HP 567
Alternative Names: HP-567Latest Information Update: 20 Jun 2024
At a glance
- Originator Hinova pharmaceuticals
- Class Antineoplastics
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 13 Jul 2023 HP 567 is available for licensing as of 13 Jul 2023. https://www.hinovapharma.com/en/shangwuhezuo.html
- 13 Jul 2023 Preclinical trials in Cancer in China (unspecified route) prior July 2023 (Hinova Pharmaceuticals pipeline, July 2023)